Literature DB >> 9794402

A molecular basis for how a single TCR interfaces multiple ligands.

A Boesteanu1, M Brehm, L M Mylin, G J Christianson, S S Tevethia, D C Roopenian, S Joyce.   

Abstract

CD8+ T cells respond to Ags when their clonotypic receptor, the TCR, recognizes nonself peptides displayed by MHC class I molecules. The TCR/ligand interactions are degenerate because, in its life time, the TCR interacts with self MHC class I-self peptide complexes during ontogeny and with self class I complexed with nonself peptides to initiate Ag-specific responses. Additionally, the same TCR has the potential to interact with nonself class I complexed with nonself peptides. How a single TCR interfaces multiple ligands remains unclear. Combinatorial synthetic peptide libraries provide a powerful tool to elucidate the rules that dictate how a single TCR engages multiple ligands. Such libraries were used to probe the requirements for TCR recognition by cloned CD8+ T cells directed against Ags presented by H-2Kb class I molecules. When H-2Kb contact residues were examined, position 3 of the peptides proved more critical than the dominant carboxyl-terminal anchor residue. Thus, secondary anchor residues can play a dominant role in determining the antigenicity of the epitope presented by class I molecules. When the four solvent-exposed potential TCR contact residues were examined, only one or two of these positions required structurally similar residues. Considerable structural variability was tolerated at the remaining two or three solvent-exposed residues of the Kb-binding peptides. The TCR, therefore, requires close physico-chemical complementarity with only a few amino acid residues, thus explaining why TCR/MHC interactions are of low affinity and degenerate.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794402

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

Review 1.  Immune recognition, response, and regulation: how T lymphocytes do it.

Authors:  S Joyce
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

2.  A single nucleotide polymorphism in the Emp3 gene defines the H4 minor histocompatibility antigen.

Authors:  Brianna Luedtke; Laura M Pooler; Eun Young Choi; Angela M Tranchita; Corbett J A Reinbold; Aaron C Brown; Daniel J Shaffer; Derry C Roopenian; Subramaniam Malarkannan
Journal:  Immunogenetics       Date:  2003-07-04       Impact factor: 2.846

Review 3.  Discovering protective CD8 T cell epitopes--no single immunologic property predicts it!

Authors:  Pavlo Gilchuk; Timothy M Hill; John T Wilson; Sebastian Joyce
Journal:  Curr Opin Immunol       Date:  2015-02-06       Impact factor: 7.486

4.  A single-amino-acid variant of the H60 CD8 epitope generates specific immunity with diverse TCR recruitment.

Authors:  Su Jeong Ryu; Ji Yeong Jeon; Jun Chang; Thomas J Sproule; Derry C Roopenian; Eun Young Choi
Journal:  Mol Cells       Date:  2012-03-21       Impact factor: 5.034

Review 5.  Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

Authors:  R Servín-Blanco; R Zamora-Alvarado; G Gevorkian; K Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

6.  Mimotopes of tumor-associated T-cell epitopes for cancer vaccines determined with combinatorial peptide libraries.

Authors:  Tumenjargal Sherev; Karl-Heinz Wiesmüller; Peter Walden
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

7.  Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer.

Authors:  Muzamil Yaqub Want; Anna Konstorum; Ruea-Yea Huang; Vaibhav Jain; Satoko Matsueda; Takemasa Tsuji; Amit Lugade; Kunle Odunsi; Richard Koya; Sebastiano Battaglia
Journal:  Oncoimmunology       Date:  2019-03-30       Impact factor: 7.723

8.  Identification of the Targets of T-cell Receptor Therapeutic Agents and Cells by Use of a High-Throughput Genetic Platform.

Authors:  Ron S Gejman; Heather F Jones; Martin G Klatt; Aaron Y Chang; Claire Y Oh; Smita S Chandran; Tatiana Korontsvit; Viktoriya Zakahleva; Tao Dao; Christopher A Klebanoff; David A Scheinberg
Journal:  Cancer Immunol Res       Date:  2020-03-17       Impact factor: 11.151

9.  Residue analysis of a CTL epitope of SARS-CoV spike protein by IFN-gamma production and bioinformatics prediction.

Authors:  Jun Huang; Yingnan Cao; Xianzhang Bu; Changyou Wu
Journal:  BMC Immunol       Date:  2012-09-10       Impact factor: 3.615

10.  Selection of Thymocytes Expressing Transgenic TCR Specific for a Minor Histocompatibility Antigen, H60.

Authors:  Ji-Min Ju; Min Bum Kim; Su Jeong Ryu; Joo Young Kim; Jun Chang; Eun Young Choi
Journal:  Immune Netw       Date:  2015-10-26       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.